Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novacta Biosystems Ltd.

www.novactabio.com

Latest From Novacta Biosystems Ltd.

Antibiotics charity wants new regimens not just new drugs

Amid mounting concern surrounding antibiotic resistance, charity Antibiotic Research UK says new ideas are needed in this particular research space focused on keeping current drugs in use and not just on creating new products.

Cancer

The rest is Silence as Christély hands over to Sedgwick

Thomas Christély, who was made CEO of Silence Therapeutics in September 2011 after rising through the executive ranks following his instrumental role in merging the company with Atugen (scripintelligence.com, 20 September 2011), has resigned for personal reasons and given up his place on the board. He will be succeeded by Dr Tony Sedgwick, who also joined Silence in September 2011 as chief business officer. Dr Sedgwick was previously CEO of Novacta Biosystems and chair of Plastid. Dr Georg Buchner, who was brought on board by Dr Sedgwick in October 2011, also from Novacta Biosystems, will take full responsibility for the business development team.

DSM BioSolutions to make Novacta's lantibiotic candidate for tests

DSM BioSolutions has entered into an agreement with Novacta Biosystems of the UK, under which it will manufacture Novacta's lantibiotic candidate for pre-clinical and Phase I clinical trials, as a treatment for Clostridium difficile infection. No financial terms have been disclosed.

Infectious Diseases Netherlands

Private investment round-up: July 2009

The number of private companies securing investments took a sizeable leap last month, as a number of small financing rounds added to some heavyweight deal making, a Scrip analysis has found.

Infectious Diseases Canada
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Novacta Biosystems Ltd.
  • Senior Management
  • Mike Dawson, PhD, CSO
    Georg Buchner , PhD, VP, Corp & Bus. Dev.
  • Contact Info
  • Novacta Biosystems Ltd.
    Phone: (44) 1707 356130
    BioPark Hertfordshire, Broadwater Rd.
    Welwyn Garden City, AL7 3AX
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register